Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-upYves Fradet, Dean F. Bajorin, David I. Quinn et al.|Annals of Oncology|2019Cited by 484